Bluebird Bio (BLUE) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Bluebird Bio (BLUE) reported a Q3 loss of $0.31 per share, which was better than the expected loss of $0.38 per share. However, the company lagged in revenue estimates.
November 14, 2024 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bluebird Bio reported a Q3 loss of $0.31 per share, better than the expected $0.38 loss, but missed revenue estimates.
The better-than-expected EPS loss is a positive sign, but missing revenue estimates could offset this. The mixed results may lead to neutral short-term stock movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100